☆ 4.8 Editorial Material

Monoclonal Antibody Therapy in Parkinson's Disease - The End?

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Trial of Prasinezumab in Early-Stage Parkinson's Disease

G. Pagano et al.

Summary: The study found that prasinezumab had no meaningful effect on global or imaging measures of Parkinson's disease progression and was associated with infusion reactions.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Trial of Cinpanemab in Early Parkinson's Disease

A. E. Lang et al.

Summary: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Editorial Material Neurosciences

The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions

Jack C. de la Torre et al.

JOURNAL OF ALZHEIMERS DISEASE (2021)

添加到收藏夹

Article Neurosciences

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Werner Poewe et al.

Summary: This phase 1 study evaluated the safety and tolerability of PD03A in patients with early Parkinson's disease, with all patients experiencing at least one adverse event. A substantial IgG antibody response against PD03 was observed, reaching maximum titers at Week 12. The differences in titers between the active groups and placebo were statistically significant from the second immunization at Week 8 until Week 52, supporting the further development of active immunotherapeutic approaches for PD treatment.

JOURNAL OF PARKINSONS DISEASE (2021)

添加到收藏夹

Review Clinical Neurology